跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8,172 条关于
“PI3Kα-RAS”
全部
8,172
临床试验
4,137
药物
547
机构
220
资讯
3,268
11个月前
Frontier Medicines Unveils FMC-242, Novel PI3Kα/RAS Inhibitor Targeting Cancer's Most Common Genetic Drivers
去年
BBOT's BBO-10203 Shows Broad Anti-Tumor Activity in Science Publication, Advances to Phase 1 Trial
上个月
BBOT Advances Triple KRAS-PI3Kα Pipeline with Dual Combination Dosing, Reports $344M Cash Runway into 2028
5个月前
Frontier Medicines Appoints Former Seagen CEO David Epstein to Board as Company Advances Covalent Precision Medicine Pipeline
去年
BBOT Completes $382 Million SPAC Merger to Advance Next-Generation RAS-Targeted Cancer Therapeutics
9个月前
BBOT Presents First-in-Class RAS:PI3Kα Breaker BBO-10203 Data at SABCS, Launches Phase 1 Trial
去年
Vividion Therapeutics Initiates Phase I Trial of Novel RAS-PI3Kα Inhibitor for Advanced Solid Tumors
去年
Vividion Secures Exclusive Rights to First-in-Class WRN Inhibitor VVD-214 for MSI-High Cancers
去年
Lilly to Acquire Scorpion Therapeutics' Mutant-Selective PI3Kα Inhibitor Program for $2.5 Billion
去年
FDA Approves PI3Kα Inhibitor/Degrader Alpelisib for Advanced Breast Cancer
第 1 页,共 327 页
上一页
下一页